Niagen Bioscience Inc
$3.75+2.18%(+$0.08)
TickerSpark Score
76/100
70
Valuation
95
Profitability
100
Growth
84
Health
30
Momentum
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NAGE research report →
52-Week Range2% of range
Low $3.56
Current $3.75
High $14.69
Companywww.niagenbioscience.com
Niagen Bioscience Inc is a bioscience company dedicated to healthy aging. The Company leads research on nicotinamide adenine dinucleotide.
- CEO
- Robert N. Fried
- IPO
- 2015
- Employees
- 104
- HQ
- Los Angeles, CA, US
Price Chart
-65.15% · this period
Valuation
- Market Cap
- $298.67M
- P/E
- 16.08
- P/S
- 2.29
- P/B
- 3.64
- EV/EBITDA
- 17.56
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 64.28%
- Op Margin
- 8.51%
- Net Margin
- 14.29%
- ROE
- 25.38%
- ROIC
- 11.35%
Growth & Income
- Revenue
- $129.42M · 29.95%
- Net Income
- $17.38M · 103.30%
- EPS
- $0.22 · 120.00%
- Op Income
- $14.30M
- FCF YoY
- 10.04%
Performance & Tape
- 52W High
- $14.69
- 52W Low
- $3.56
- 50D MA
- $4.55
- 200D MA
- $6.63
- Beta
- 2.17
- Avg Volume
- 1.23M
Get TickerSpark's AI analysis on NAGE
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 24, 26 | Fried Robert N | other | 20,000 |
| Apr 24, 26 | Fried Robert N | other | 20,000 |
| Feb 19, 26 | Lopez Carlos Luis | other | 41,420 |
| Feb 19, 26 | Pamir Ozan | other | 62,131 |
| Feb 19, 26 | Fried Robert N | other | 503,937 |
| Nov 14, 25 | Pamir Ozan | buy | 4,464.962 |
| Nov 14, 25 | Pamir Ozan | buy | 2,220.443 |
| Jun 24, 25 | Shahbazi Hamed | other | 20,000 |
| Jun 24, 25 | YU Wing Tak Wendy | other | 20,000 |
| Jun 24, 25 | Patrick Kristin | other | 20,000 |
Our NAGE Coverage
We haven't published any research on NAGE yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate NAGE Report →Similar Companies
OLMA+6.56%
Olema Pharmaceuticals, Inc.
$13.96
CRVS+6.00%
Corvus Pharmaceuticals, Inc.
$12.19
PRTA+3.09%
Prothena Corporation plc
$9.35
VTYX+0.00%
Ventyx Biosciences, Inc.
$14.00
KROS+10.80%
Keros Therapeutics, Inc.
$10.98
AKBA+12.84%
Akebia Therapeutics, Inc.
$1.01
RIGL+1.84%
Rigel Pharmaceuticals, Inc.
$28.82
ZVRA+0.39%
Zevra Therapeutics, Inc.
$10.24